Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).
Ryan P, Berenguer J, Ramos-Ruperto L, Vera M, Martín-Carbonero L, Pérez-Latorre L, De Los Santos I, Pinto A, Vivancos MJ, Orviz E, Álvarez B, Sanz J, Ruiz-Seco P, Torres R, Brazal B, De Miguel M, López-Centeno B, Jarrín I, Resino S, Bellón JM, González-García J. Ryan P, et al. Among authors: orviz e. Open Forum Infect Dis. 2025 Nov 6;12(12):ofaf678. doi: 10.1093/ofid/ofaf678. eCollection 2025 Dec. Open Forum Infect Dis. 2025. PMID: 41311917 Free PMC article.
Diagnosis of HIV infection during pregnancy: Trends from a national cohort in Spain.
Suárez-García I, Alejos B, Moreno C, Izquierdo R, de la Cámara SP, Resa-Infante P, Merino VS, García-Arriaza J, Cabello-Úbeda A, Pérez-Martínez L, Palacios R, Hernando V, Jarrín I; CoRIS cohort. Suárez-García I, et al. HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70148. Online ahead of print. HIV Med. 2025. PMID: 41267621
Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial).
Ambrosioni J, de Lazzari E, Sánchez-Palomino S, Bailón L, Suanzes P, Busca C, Ramos-Ruperto L, Orviz E, Rivero Á, Mothe B, Romero JD, Falcó V, Vicens-Artés S, Moraga E, Cruceta A, Mallolas J, Miró JM; BIC-PHI Study Group. Ambrosioni J, et al. Among authors: orviz e. J Infect. 2025 Nov;91(5):106651. doi: 10.1016/j.jinf.2025.106651. Epub 2025 Nov 7. J Infect. 2025. PMID: 41207637 Free article.
Screening for asymptomatic mpox in at-risk populations: A cross-sectional study.
Armenteros-Yeguas I, Homen R, Valls A, Dans L, Orviz E, Ayerdi O, Puerta T, Vera M, Pérez-García JA, Torres M, Coiras M, Del Romero J, Estrada V. Armenteros-Yeguas I, et al. Among authors: orviz e. PLoS One. 2025 Oct 30;20(10):e0335729. doi: 10.1371/journal.pone.0335729. eCollection 2025. PLoS One. 2025. PMID: 41166295 Free PMC article.
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size.
De La Torre Tarazona E, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, García Fraile LJ, Peraire J, Garcia-Gasalla M, Balsalobre L, Guillén Martínez S, López Cortés LF, Jarrín I, Serrano-Villar S, Alcamí J, Moreno S; CoRIS Cohort. De La Torre Tarazona E, et al. Sci Rep. 2025 Jul 13;15(1):25306. doi: 10.1038/s41598-025-09474-1. Sci Rep. 2025. PMID: 40653494 Free PMC article.
Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations.
Suñer C, Escrig-Sarreta R, Galván-Casas C, Matos E, Gabster A, Wolff M, Ouchi D, Alemany A, Sánchez H, Huaman S, Bejarano D, Carrés-Esteve L, Santiago-Fernández C, Corral-Rubio J, Mendoza A, Rivero À, Descalzo V, Orviz E, Martínez-Riveros H, Méndez-Boo L, Cabezas C, Arce-Arnáez A, Marks M, Mitjà O, Remain Study Group. Suñer C, et al. Among authors: orviz e. Vaccines (Basel). 2025 May 30;13(6):594. doi: 10.3390/vaccines13060594. Vaccines (Basel). 2025. PMID: 40573925 Free PMC article.
Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study.
Pérez-Valero I, Corona Mata D, Camacho Espejo A, Gallo M, García-Ruiz de Morales AG, Fanciulli C, Martín-Carbonero L, Calzado Isbert S, Hernández Gutiérrez C, Asensi V, Rivero Juarez A, Rivero A; Cohorte de la Red Española de Investigación en SIDA (CoRIS) Cohort. Pérez-Valero I, et al. Clin Infect Dis. 2025 Nov 6;81(4):e93-e101. doi: 10.1093/cid/ciaf162. Clin Infect Dis. 2025. PMID: 40152537 Free PMC article.
Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
Izquierdo R, Suárez-García I, Marco-Sánchez C, Pérez-Latorre L, Riera M, Cano J, Viladés C, Reus S, Olalla J, González-Ruano P, Orviz E, Díaz A, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. Among authors: orviz e. HIV Med. 2025 Apr;26(4):606-620. doi: 10.1111/hiv.13762. Epub 2025 Jan 21. HIV Med. 2025. PMID: 39835516 Free PMC article.
40 results